GGHC
DNTH icon

Gilder Gagnon Howe & Co’s Dianthus Therapeutics DNTH Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-44,076
Closed -$994K – 250
2022
Q3 		$994K Sell
44,076
-2,548
-5% -$69.8K 0.02% 198
2022
Q2 		$895K Sell
46,624
-164,867
-78% -$4.07M 0.02% 203
2022
Q1 		$9.81M Sell
211,491
-18,235
-8% -$996K 0.09% 142
2021
Q4 		$16.3M Sell
229,726
-5,946
-3% -$598K 0.09% 151
2021
Q3 		$27.5M Sell
235,672
-20,735
-8% -$2.42M 0.14% 135
2021
Q2 		$40.1M Sell
256,407
-5,431
-2% -$998K 0.2% 120
2021
Q1 		$49.6M Sell
261,838
-1,800
-0.7% -$303K 0.27% 100
2020
Q4 		$33.1M Sell
263,638
-2,942
-1% -$334K 0.16% 125
2020
Q3 		$29M Sell
266,580
-4,276
-2% -$507K 0.18% 119
2020
Q2 		$32.5M Buy
270,856
+17,119
+7% +$2.41M 0.25% 98
2020
Q1 		$25.5M Sell
253,737
-2,727
-1% -$505K 0.31% 92
2019
Q4 		$62.2M Sell
256,464
-2,703
-1% -$505K 0.65% 57
2019
Q3 		$42.5M Sell
259,167
-1,645
-0.6% -$312K 0.49% 66
2019
Q2 		$61.6M Buy
260,812
+146,485
+128% +$36.2M 0.62% 58
2019
Q1 		$30.1M Buy
+114,327
New +$19.7M 0.32% 80

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Gilder Gagnon Howe & Co's DNTH Position: Q4 2022 in Review

Gilder Gagnon Howe & Co sold out of Dianthus Therapeutics (DNTH) in Q4 2022, closing a stake of 44,076 shares — an estimated $994K sold.

Gilder Gagnon Howe & Co first reported a position in DNTH in Q1 2019 and held it in 15 quarters. The position peaked at $62.2M in Q4 2019. 53 funds tracked by Wall St. Rank hold DNTH as of Q4 2022.

  • Gilder Gagnon Howe & Co reported no remaining Dianthus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 44,076 Dianthus Therapeutics shares in Q4 2022, an estimated $994K.
  • Gilder Gagnon Howe & Co first reported a position in Dianthus Therapeutics in Q1 2019 and held it in 15 quarters.
  • Gilder Gagnon Howe & Co's Dianthus Therapeutics position peaked at $62.2M in Q4 2019.
  • 53 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2022.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2022, filed 14 Feb 2023.